Combination Chemotherapy With Vinblastine, Bleomycin, Cisplatin, and Etoposide (VBPE) in Children With Primary Intracranial Germ Cell Tumors

Te‐Kau ‐K Chang, Tai-Tong Wong, Betau Hwang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We have treated 13 children with primary intracranial germ cell tumors with the combination of vinblastine, bleomycin, cisplatin, and etoposide, the so‐called VBPE regimen in the past seven years at one institution. The clinical diagnosis of these children were: three germinomas, seven non‐germinomatous germ cell tumors, and three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. Of this group, three germinomas and three non‐germinomatous germ cell tumors were treated primarily with VBPE plus radiotherapy. All of them responded completely, and were free of tumor. Primary VBPE regimen without radiotherapy was used in another four non‐germinomatous germ cell tumors. After six courses of VBPE regimen, only one of the four patients achieved complete response for 30 months. VBPE regimen was used as salvage chemotherapy in three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. After six courses of VBPE regimen, two had complete response for 58+ months and 78+ months respectively. We concluded that in newly‐diagnosed intracranial non‐germinomatous germ cell tumors, the combination of chemotherapy VBPE regimen and radiotherapy led to good results. Primary chemotherapy with VBPE alone was not adequate for the treatment of non‐germinomatous germ cell tumors. However, VBPE regimen might be one of the salvage therapies for recurrent germ cell tumors without chemotherapy before relapse. © 1995 Wi1ey‐Liss, Inc.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalMedical and Pediatric Oncology
Volume24
Issue number6
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Vinblastine
Germ Cell and Embryonal Neoplasms
Bleomycin
Etoposide
Combination Drug Therapy
Cisplatin
Drug Therapy
Germinoma
Radiotherapy
Salvage Therapy
Recurrence

Keywords

  • brain neoplasm
  • chemotherapy
  • children
  • germinoma
  • germ‐cell tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Combination Chemotherapy With Vinblastine, Bleomycin, Cisplatin, and Etoposide (VBPE) in Children With Primary Intracranial Germ Cell Tumors. / Chang, Te‐Kau ‐K; Wong, Tai-Tong; Hwang, Betau.

In: Medical and Pediatric Oncology, Vol. 24, No. 6, 01.01.1995, p. 368-372.

Research output: Contribution to journalArticle

@article{700d204ad2d7471aa6e59e947103695b,
title = "Combination Chemotherapy With Vinblastine, Bleomycin, Cisplatin, and Etoposide (VBPE) in Children With Primary Intracranial Germ Cell Tumors",
abstract = "We have treated 13 children with primary intracranial germ cell tumors with the combination of vinblastine, bleomycin, cisplatin, and etoposide, the so‐called VBPE regimen in the past seven years at one institution. The clinical diagnosis of these children were: three germinomas, seven non‐germinomatous germ cell tumors, and three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. Of this group, three germinomas and three non‐germinomatous germ cell tumors were treated primarily with VBPE plus radiotherapy. All of them responded completely, and were free of tumor. Primary VBPE regimen without radiotherapy was used in another four non‐germinomatous germ cell tumors. After six courses of VBPE regimen, only one of the four patients achieved complete response for 30 months. VBPE regimen was used as salvage chemotherapy in three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. After six courses of VBPE regimen, two had complete response for 58+ months and 78+ months respectively. We concluded that in newly‐diagnosed intracranial non‐germinomatous germ cell tumors, the combination of chemotherapy VBPE regimen and radiotherapy led to good results. Primary chemotherapy with VBPE alone was not adequate for the treatment of non‐germinomatous germ cell tumors. However, VBPE regimen might be one of the salvage therapies for recurrent germ cell tumors without chemotherapy before relapse. {\circledC} 1995 Wi1ey‐Liss, Inc.",
keywords = "brain neoplasm, chemotherapy, children, germinoma, germ‐cell tumor",
author = "Chang, {Te‐Kau ‐K} and Tai-Tong Wong and Betau Hwang",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/mpo.2950240606",
language = "English",
volume = "24",
pages = "368--372",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Combination Chemotherapy With Vinblastine, Bleomycin, Cisplatin, and Etoposide (VBPE) in Children With Primary Intracranial Germ Cell Tumors

AU - Chang, Te‐Kau ‐K

AU - Wong, Tai-Tong

AU - Hwang, Betau

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We have treated 13 children with primary intracranial germ cell tumors with the combination of vinblastine, bleomycin, cisplatin, and etoposide, the so‐called VBPE regimen in the past seven years at one institution. The clinical diagnosis of these children were: three germinomas, seven non‐germinomatous germ cell tumors, and three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. Of this group, three germinomas and three non‐germinomatous germ cell tumors were treated primarily with VBPE plus radiotherapy. All of them responded completely, and were free of tumor. Primary VBPE regimen without radiotherapy was used in another four non‐germinomatous germ cell tumors. After six courses of VBPE regimen, only one of the four patients achieved complete response for 30 months. VBPE regimen was used as salvage chemotherapy in three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. After six courses of VBPE regimen, two had complete response for 58+ months and 78+ months respectively. We concluded that in newly‐diagnosed intracranial non‐germinomatous germ cell tumors, the combination of chemotherapy VBPE regimen and radiotherapy led to good results. Primary chemotherapy with VBPE alone was not adequate for the treatment of non‐germinomatous germ cell tumors. However, VBPE regimen might be one of the salvage therapies for recurrent germ cell tumors without chemotherapy before relapse. © 1995 Wi1ey‐Liss, Inc.

AB - We have treated 13 children with primary intracranial germ cell tumors with the combination of vinblastine, bleomycin, cisplatin, and etoposide, the so‐called VBPE regimen in the past seven years at one institution. The clinical diagnosis of these children were: three germinomas, seven non‐germinomatous germ cell tumors, and three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. Of this group, three germinomas and three non‐germinomatous germ cell tumors were treated primarily with VBPE plus radiotherapy. All of them responded completely, and were free of tumor. Primary VBPE regimen without radiotherapy was used in another four non‐germinomatous germ cell tumors. After six courses of VBPE regimen, only one of the four patients achieved complete response for 30 months. VBPE regimen was used as salvage chemotherapy in three recurrent non‐germinomatous germ cell tumors without previous chemotherapy. After six courses of VBPE regimen, two had complete response for 58+ months and 78+ months respectively. We concluded that in newly‐diagnosed intracranial non‐germinomatous germ cell tumors, the combination of chemotherapy VBPE regimen and radiotherapy led to good results. Primary chemotherapy with VBPE alone was not adequate for the treatment of non‐germinomatous germ cell tumors. However, VBPE regimen might be one of the salvage therapies for recurrent germ cell tumors without chemotherapy before relapse. © 1995 Wi1ey‐Liss, Inc.

KW - brain neoplasm

KW - chemotherapy

KW - children

KW - germinoma

KW - germ‐cell tumor

UR - http://www.scopus.com/inward/record.url?scp=0029057325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029057325&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950240606

DO - 10.1002/mpo.2950240606

M3 - Article

VL - 24

SP - 368

EP - 372

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -